Patrick Lamy - 08 Dec 2023 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Senior Vice President, Commercial Strategy
Signature
/s/ Jonathan Young, Attorney-in-Fact
Issuer symbol
AKRO
Transactions as of
08 Dec 2023
Net transactions value
$0
Form type
4
Filing time
12 Dec 2023, 16:35:07 UTC
Previous filing
11 Jan 2023
Next filing
13 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Award $0 +18,570 $0.000000 18,570 08 Dec 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Award $0 +83,564 $0.000000 83,564 08 Dec 2023 Common Stock 83,564 $19.87 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in eight (8) equal semi-annual installments, commencing from December 8, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
F2 This option shall vest and become exercisable in forty-eight (48) equal monthly installments, commencing from December 8, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

Remarks:

Senior Vice President, Commercial Strategy